Decision-Making under Uncertain Conditions: The Internist, as a Director of the Diagnostic/Therapeutic Pathway in Grey Zones

Daniela Tirotta*  
Vittorio Durante1

1Department of Internal Medicine, Cervesi Hospital (AUSL Romagna), Cattolica, Italy

Abstract

The internists should utilize both their clinic experience and medical literature's evidences, mediating with organizational context, patients' opinion and ethics. However, none of these components may be sufficient.

In several medical sectors, we may find many and extensive grey zones in which a diagnostic intervention's effectiveness and/or its alternatives are uncertain.

This cannot lead to the decision-making process's paralysis, because the evidence-based medicine requires to base any clinical decision on "the best available evidences" and not on "the best possible evidences."

Clinicians should be able to extrapolate the prevailing question structuring from patients' problem [PICO: problem, intervention, confront, outcome]; identify the best available evidence and synthesize it; perform critical evaluation and information transfer (critical appraisal); in clinical efficiency, evaluate any action options.

Keywords
Hospitalist; Internal Medicine; Clinical Error; Complexity

In general, medicine is considered as an inexact science for three main reasons:

Failure rate and uncertainty are secondary to clinical error (being it cognitive or system flaws-related: clinical risk)

Statistician William Deming showed how reduced is the acceptable failure rate in several major business sectors "If we had to tolerate living with a level of efficiency equal to 99.9 % we would have two dangerous landings a day, only in the O'Hare airport in Chicago. Every hour there would be 16,000 failed correspondence addresses, and 32,000 bank cheques withdrawn from a wrong bank account."

In comparison, medical practice exhibits a remarkable anomaly. If the error extent is underestimated, the poor understanding of its nature is alarming as well.

In a recent study, physicians attributed the main failure rate to undersized staff combined with work overload while they did not mention cognitive causes. However, several studies show that the 1/6 of medical errors occurs synthetizing available informations or deciding to act according to these [1,2].

Failure rate is inherent in diagnostic process itself, which is highly probabilistic

For example, for a proper diagnosis, diagnostic tests are not enough, because they seldom give conclusive results. Tests sensibility and specificity are inherent characteristics, which are usually provided by test manufacturers, or can be found in the literature. They determine also [3]:

a. Diagnosis variability: positive or negative predictive value is influenced by disease prevalence.

b. Biological variability of signs and symptoms' occurrence: Vital signs (blood pressure and heart rate) may vary on a daily basis and independently of other factors (position, diet, stress, physical activity etc.) In addition, many measurements, including those resulting from echocardiograms (for example, ejection fraction), are variable as well.

c. Cultural and scientific position: As to continuous measurements, such as sow blood pressure, body mass, cholesterol or glucose tolerance, which cannot be expressed by "positive-negative" dichotomy, the identification of a pathological threshold is arbitrary (as it changes with new scientific data, industrial interests, economic sustainability).

d. Complex clinic judgment: Just as happens in any other field, even in the medical area the same event can be interpreted in different ways, by different observers and at different times.

*Corresponding author:
Daniela Tirotta  
Department of Internal Medicine  
Cervesi Hospital (AUSL Romagna)  
Cattolica, Italy.  
Tel: +39-0541-966291  
E-mail: danitirotta@libero.it

Citation: Tirotta D, Durante V. Decision-making under uncertain conditions: the internist, as a director of the diagnostic/therapeutic pathway in grey zones. Int J Clin Med Cases. 2018 Jan;1(1):101

Copyright: © 2018 Tirotta D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
e. Economic elements introduction in health management: with secondary waste concepts (resources use, which does not change the results related to: quantity or underutilization, quality; failed exclusion despite procedures of unproven effectiveness), saving: less resources use (amount of resources used) and cheapness: proper use of resources (quality/quantity of resources used) [3,4].

Failre rate is related to lack of evidences and grey zones presence

A recent paper published in the New England Journal of Medicine points out that one crucial issue may be the perception that health care is a twofold world in which interventions are either effective or ineffective, appropriate or inappropriate. Actually, there are large grey zones in which interventions are neither clearly effective nor ineffective —where benefits are unknown or uncertain and values may depend on patients’ preferences and available alternatives.

Moreover, although principle guidelines focus on “appropriateness,” we should underline that appropriate care is not the same as necessary care. Many areas of medicine have recently undergone near continuous innovation process (imaging, cardiology, oncology, and orthopedics), which involved a rapid cost growth. Unfortunately, new tools “appropriate” use mostly occurs in grey zones where, although a procedure is unlikely to be harmful, its benefits may be modest or unproven [5].

As hospitalists, internists should utilize both their clinic experience and medical literature’s “evidences”, mediating with organizational context, patients’ opinion and ethics. However, none of these components may be sufficient.

In several medical sectors, we may find many and extensive grey zones in which a diagnostic intervention’s effectiveness and/or its alternatives are uncertain.

This cannot lead to the decision-making process’s paralysis, because the evidence-based medicine requires to base any clinical decision on “the best available evidences” and not on “the best possible evidences.”

Clinicians should be able to:

1. Extrapolate the prevailing question structuring from patients’ problem (PICO: problem, intervention, confront, outcome)
2. Identify the best available evidence and synthesize it.
3. Perform critical evaluation and information transfer (critical appraisal).
4. In clinical efficiency, evaluate any action options: internists should always wonder whether these will produce:
   - more positive than negative effects (efficacy)
   - Proper functioning in usual clinical practices circumstances (effectiveness)
   - Benefits in relation to the resources used (efficiency), and
   - Potential risks.

As an example, we will report some cases related to internists’ clinical decision-making process in the grey zones.

Case 1: Therapeutic decision for a usual pathology, but with an unusual presentation

Clinical case: A 55-year-old man has come to our ultrasound outpatient department because of hematuria. Abdominal ultrasound showed two, bilateral, hypoechoic and non-homogeneous large renal masses (right: 10 cm, left: 7 cm, respectively).

Laboratory tests showed that creatinine and glomerular filtration rate were still within acceptable limits (creatinine: 1.2; glomerular filtration rate: GFR 60 ml/min).

The patient underwent tomographic evaluation of his illness along with urological assessment: the urologist gave no indications for the chisurgical approach, but suggested anti-tyrosine kinase therapy.

Background: The diagnosed pathology (Renal Cell Carcinoma: RCC bilateral synchronous) is quite unusual.

Do we have necessary evidences for a therapeutic procedure? Is the decision not to perform surgery secondary to cognitive bias (diagnostic-therapeutic inertia/ omission bias)?

Clinical problem (PICO): In a patient with massive renal synchronous neoplasia (RCC), is medical therapy, compared to surgical therapy, the only way to improve survival?

Best available evidence identification: Nephrectomy is usually recommended as a first step in RCC. However, since the observed pathology (massive renal synchronous neoplasia) is unusual, routine recommendations cannot apply. Medline Literature’s extensive research features only observational studies, retrospective and international registers. It emerges that the extent of the disease has no significant influence on the decision to perform surgery.

Patients with estimated survival time equal to < 12 mo or 4 further IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) prognostic factors may not benefit from nephrectomy whereas all other patients do [6-8].

Internist - Patient communication: After being informed on risks (especially, the probable, imminent necessity for a dialysis approach) and benefits (complete mass removal), the patient opted for a radical surgery approach.

Evolution: Considering patient’s young age, good performance status, medical history and will, the internist asked for a second opinion in another Medical Center with a high number of relevant clinical cases (as recommended in case of unusual diseases), where the man underwent radical (right side) and partial (left side) nephrectomy. One year later, he is still asymptomatic with good GFR.

Case 2: Diagnostic – Therapeutic decisions related to unusual pathology

Clinical case: In the last months, a 60-year-old woman has experienced progressive asthenia, fever and paraplegia due to a voluminous retroperitoneal, paravertebral mass which was difficult to get access to, confirmed by abdominal tomography (TC).

We performed a guided TC biopsy (repeated twice because of initially insufficient evidences) that showed a suspicious lymphoma with two components:

- low kinetic phenotype index with germinal center.
- T-cells with high proliferative index/large cell B.

The slides were examined also in another reference center, where they confirmed the apparent double population, although histological report was lacking Negative osteomodulary biopsy.

Clinical problem (PICO): In a patient with a probable composite lymphoma, has a histological characterization the greatest impact on survival, even with diagnostic latency increase, or is a therapy tout court more appropriate, considering the available histology?

Background: A composite lymphoma consists of two or more different morphological types of malignant lymphoma affecting the same organ or tissue. Most of the reported cases show a combination of classic Hodgkin lymphoma with B-cell lymphoma. The co-occurrence of B and T cell lymphoma, however, is a rare event. Does therapeutic latency, justified by hardly-obtained detailed diagnostics, worsen the prognosis only?

Best available evidence identification: Only case reports with aggressive course are reported. In response cases, a correct histological characterization is crucial to ensure greater therapeutic appropriateness [9-16].

Internist - patient communication: We talked to the patient and his family, pointing out the difficulties her diagnosis involved, due both to the mass ubication, and disease severity. We considered to adopt a diagnostic surgical approach, although difficult to implement. She asked to be moved to another Hematology department where she started the therapy.
**Evolution:** The patient started the therapy for lymphoma B with high proliferative index. The evolution was unfavourable. Even so, following a meeting, a decision was taken by common agreement between the internist, the hematologist colleagues, the patient and her family. Unfortunately, the patient died 5 months later.

**Case 3: Diagnostic and therapeutic decision related to a non-recurring pathology, with confounding bias**

**Clinical Case:** Two years ago, a 55-year-old man came to our outpatient department with a chronic hepatitis B and hepatic injury, which was interpreted as an angioma. His medical history was negative, especially for alcohol/smoke abuse. Liver tests were normal. He underwent US abdomen positive for multiple liver hyperechoic nodules, attributed to hemangiomas, but of uncertain nature, with abdomen CT/MRI performed 3 months before. FDGD PET was negative.

**Clinical problem (PICO):** In a patient with chronic hepatitis B, should the presence of hepatic hyperechoic lesions be further investigated for a better diagnostic outcome?

**Background:** Patients affected by rare diseases find it hard to obtain good quality healthcare, due, among the others, to lack of scientific and multidisciplinary healthcare knowledge as well as to diagnostic delays. Cognitive bias accounts for late diagnosis and ineffective therapeutic path, especially in the case of rare diseases such as NET (neuroendocrine tumor), a long-recognized disease (just like 90% of NET).

Internists’ role is to analytically reason on this diagnosis, and introduce the patient to a multidisciplinary path.

Best available evidence identification: The guidelines suggest that any injury in an unhealthy liver should be further investigated with the highest possible level of evidence. The confounding bias here was the exclusion of the most common pathologies, for the expectation phenomenon [Ascertainment bias] [17-19].

**Evolution:** We performed CEUS (suggestive of metastases) and liver biopsy, positive for NET metastases (GRAD1, Ki67 2%).

However, according to the most recent NET guidelines, after discussing with the patient and the NET Reference Centre, we performed Ga68DOTANOC PET, positive for focal hypermetabolic area in terminal ileum, mesenteric adenopathy, pericardial and multiple liver nodules [18-19].

The patient started the therapy including Sandostatin LAR (1 for every 28 days) and ocreotide (0.1 x 2 for 7 days) and underwent ileal resection and cholecystectomy.

After 3 months’ therapy he underwent radiometabolic therapy and now, after one year, he is in good clinical conditions.

Clinical reasoning should allow for the inclusion of an unusual pathology and should organize a multidisciplinary path.

**Conclusion**

**Appropriateness** is commonly understood as "the level of assistance really necessary to the patient, for so it can be appropriate to the best and newest available scientific evidences."

Any "appropriate" decision complies with the six right things’ rule: the right medication, for the right individual, in the right moment, from a right professional, in the right dose, with the right documentation. Actions’ quality needs to be considered in relation both to objectives and execution mode [20].

From the examined cases we clearly infer that medicine is a complex system. The internists’ cultural background can be a helpful guide in grey zones and beyond, by mediating six fundamental points of view: the patient, the doctor, the evidences, the non-evidences, the organizational/social/economic context and the inter-professional cooperation (Figure 1).

---

**Figure 1:** Complexity of medicine and role of the internist

**References**

1. Newman-Toker DE, Pronovost PJ. Diagnostic Errors the next frontier for patient safety. JAMA. 2009 Mar;301(10):1060-1062.

2. Bendlon RJ, DesRoches CM, Brodie M, Benson JM, Rosen AB, et al. Views of practicing physicians and the public on medical errors. N Engl J Med. 2002 Dec;347(24):1933-1940.

3. Nardi R. Quale "appropriatazza" per la decisione clinica in medicina interna? Which appropriateness for clinical decision making in Internal Medicine? Italian Journal of Medicine. 2008;2(4):1-3.

4. Calmer A. The managing tools of human resources in hospitals. Jesi: Bossard Consultants, SmithKline Beecham, 1995.

5. Chandra A, Khullar D, Lee TH. Addressing the challenge of gray-zone medicine. N Engl J Med. 2015 Jan;372(3):203-205.

6. Laguna MP. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. J Urol. 2015 May;193(5):1514-1515.

7. Heng D,Y.Wells JC, Rini BI, Reutebuch E, Lee JL, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2014 Oct;66(4):704-710.

8. De Bruin RE, Nijikamp J, Noe A, Horenblas S, Haenen JB, et al. Baseline tumor volume in assessing prognosis of patients with intermediate-risk synchronous metastatic renal cell carcinoma. Urol Oncol. 2016 Jun;34(6):258.e7-258.e13.

9. Klatte T. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2015 Oct;68(4):737-741.

10. Liu Y, Li P, Guo Y, Fan L, Wang L, et al. A unique composite follicular lymphoma and mantle cell lymphoma with a mixed cell pattern and aggressive course. Am J Clin Pathol. 2014 May;141(5):737-741.

11. Wang HW, Yang W, Wang L, Lu YL, Lu JY. Composite diffuse
large B-cell lymphoma and classical Hodgkin’s lymphoma of the stomach: case report and literature review. World J Gastroenterol. 2013 Oct;19(37):6304-6309.

12. Whitling NA, Shanesmith RP, Jacob L, McBurney E, Sebastian S, et al. Composite lymphoma of mycosis fungoides and cutaneous small B-cell lymphoma in a 73-year-old male patient. Hum Pathol. 2013 Apr;44(4):670-675.

13. Dy JA, Chen SW, Chang CH, Chang ST, Kuo SY, et al. Composite lymphoma after chemotherapy with regressed diffuse large B-cell lymphoma and transformed cytotoxic T-cell lymphoma. Leuk Lymphoma. 2013 May;54(5):1101-1104.

14. Yamazaki S, Fujioka Y, Nakamura F, Ota S, Shinozaki A, et al. Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma. Pathol Int. 2011 Nov;61(11):662-666.

15. Oka K, Nagayama R, Yonekawa N, Nihei T, Sando N, et al. Concurrent gastric MALT and Hodgkin lymphoma: a case report. Int J Surg Pathol. 2012 Apr;20(2):201-204.

16. Yu G, Kong L, Qu G, Zhang Q, Wang W, et al. Composite lymphoma in the anterior mediastinum: a case report and review of the literature. Diagn Pathol. 2011 Jul;6:60.

17. Niino D, Ohsaki K, Arakawa F, Watanabe J, Kimura Y, et al. Composite T lymphoblastic leukemia/lymphoma and diffuse large B-cell lymphoma: case report. Pathol Int. 2011 Jun;61(6):363-368.

18. Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, et al. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasm of the Jejunum and Ileum. Neuroendocrinology. 2016;103(2):125-138.

19. Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, et al. Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors. Pancreas. 2013 May;42(4):557-577.

20. Angelico M, Arienti V, Bartolozzi C. Impiego della diagnostica per immagini delle lesioni focali epatiche. 2008:1-63.

21. Larry Beresford. Gray Zone Medicine: What’s a Hospitalist to Do? Medscape. 2015.